Home ivps4 2017-06-16T21:39:52+00:00

Investors Home

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.

Stock Info

Recent Press Releases

Recent News

Apr 22, 2021

Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021

SEATTLE, Wash and VANCOUVER, British Columbia, April 22, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Apr 14, 2021

Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research

Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, Wash and VANCOUVER,...

Mar 25, 2021

Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) in Addiction

Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline SEATTLE, Wash and...